Journal
CARDIOVASCULAR RESEARCH
Volume 50, Issue 2, Pages 224-231Publisher
OXFORD UNIV PRESS
DOI: 10.1016/S0008-6363(00)00302-3
Keywords
-
Categories
Funding
- NHLBI NIH HHS [HL46681, HL49989] Funding Source: Medline
- NIGMS NIH HHS [GM31304] Funding Source: Medline
Ask authors/readers for more resources
Drugs are widely recognized to vary in the beneficial and undesirable effects they produce in human subjects. The understanding that variants (polymorphisms and mutations) in the human genome are common and may well modulate both disease and its response to drugs, is a critical new concept in understanding mechanisms of drug action and their variability in human subjects. Variability can arise because of variability in genes encoding molecules of drug disposition, in genes encoding molecules that drugs target, or in genes that modulate the overall activity of the complex biological systems within which drugs act. The evolving understanding of the genetic basis of variability in response to drugs used in the treatment of sudden cardiac death has important implications not only for the treatment of patients who have survived an episode, but also for helping formulate a framework for further understanding mechanisms of drug action at the genetic level. (C) 2001 Elsevier Science B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available